Oral Vitamin D3 Effect on Inflammatory Biomarkers in Ulcerative Colitis Patients
Not applicable · Testing Vitamin D3 · 1 site · University of Veterinary and Animal Sciences, Lahore - Pakistan
Official record & contacts on ClinicalTrials.gov ↗
In plain English
What this trial is testing
This study is testing Vitamin D3 (a drug) as a possible treatment. Condition(s) listed: Ulcerative Colitis (UC).
Participants are assigned to groups by chance (randomized).
Some participants receive a placebo or sham for comparison.
It is open-label: participants know what they are receiving.
This study does not use drug-development phases (it may test a device, diet, procedure, app, or care approach).
Who can join
- Ages 20 to 40
- Any sex
Some of the main requirements, copied from the record:
- • All patients diagnosed previously by standard clinical i.e Truelove and Witts and endoscopic/ colonoscopic criteria
- Patients with moderate ulcerative colitis will be included
- Both male and female patients will be included in the study
Plus 4 more requirement(s). There are also 6 reasons someone might not be able to join (exclusion criteria). Only the trial team can confirm whether you qualify.
What's involved
- About 60 participants are expected to take part.
- Start date: 2025-09-02.
- Main results expected around 2025-12-15 (estimate from the record).
- 1 study site listed (1 marked recruiting) in Pakistan.
Main thing being measured
- Name: Change in ESR Unit: mm/hr (Baseline and week 12)
In the researchers’ words
This randomized controlled trial aims to evaluate the effect of oral vitamin D3 supplementation on inflammatory biomarkers and disease activity in Pakistani patients with moderate ulcerative colitis. Sixty patients will be randomized to receive either standard treatment alone/Placebo or standard treatment plus vitamin D3 (50,000 IU fortnightly) for 12 weeks.
This is a short automatic summary built from the official record. A fuller plain-English card is coming; until then, please read the official record.
Questions to ask your doctor and the trial team
- Am I likely to qualify, given my health history?
- What would I have to do, and how often would I need to visit?
- Could I get a placebo? What happens to my current treatment?
- What are the possible risks and benefits?
- Are travel or other costs covered?
- What happens after the trial ends?
Official details
| Status | Recruiting |
|---|---|
| Phase | Not applicable |
| Study type | Interventional |
| Conditions | Ulcerative Colitis (UC) |
| Lead sponsor | University of Veterinary and Animal Sciences, Lahore - Pakistan |
| Enrollment | 60 (estimated) |
| Start date | 2025-09-02 |
| Primary completion (est.) | 2025-12-15 |
| First posted | 2025-12-08 |
| Last updated | 2025-12-17 |
| Official title | Effect Of Oral Vitamin D3 Supplementation On Inflammatory Biomarkers In Patients With Ulcerative Colitis |
| ClinicalTrials.gov ID | NCT07269223 |
Interventions
- Vitamin D3 (Drug)
This intervention consists of oral Vitamin D3 (cholecalciferol) capsules administered every two weeks for the duration of the study. The dose is designed to raise and maintain adequate serum 25-hydroxyvitamin D levels. Participants will receive the active supplement under supervised distribution, and adherence will be monitored through supplement logs and follow-up visits
Full eligibility criteria (from the record)
Inclusion Criteria: * • All patients diagnosed previously by standard clinical i.e Truelove and Witts and endoscopic/ colonoscopic criteria * Patients with moderate ulcerative colitis will be included * Both male and female patients will be included in the study * No change in the type and dosage of their medicine over the past month * Patient with severe vitamin D deficiency (< 10 ng/mL) after screening * Patients who will provide written informed consent * Age: 20-40 year Exclusion Criteria:• Patients using Vitamin D supplement in the 3 months before the study * Patients suffering from Crohn's disease or any known autoimmune disease * Patients with mild and severe ulcerative colitis * Changes in the type and dosage of the drug during the study * Pregnant and lactating women * Patients with known kidney disease * Patients with known liver disease
Locations (1)
| Site | City | Country | Site status |
|---|---|---|---|
| University of Veterinary & Animal Sciences, Lahore | Lahore, Punjab Province | Pakistan | Recruiting |
For contacts at each site, use the official record.
Information only, not medical advice. Talk to your doctor and the trial team before making any decision about a clinical trial.